Please login to the form below

Not currently logged in
Email:
Password:

Jonathan Fox leaves AstraZeneca for MyoKardia

Will lead programme to target genetic heart disease

Jonathan Fox, MyoKardiaMyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer.

In his new role, Dr Fox will lead the development of the US biopharma's pipeline of small molecule therapeutics that focus on the treatment of genetic cardiovascular disease.

It's an area that Dr Fox has great experience, having served as senior director, clinical cardiovascular research at Merck & Co and director of clinical pharmacology at SmithKline Beecham, in addition to his time at AstraZeneca.

On top of this industry experience, Dr Fox has been a clinical professor of medicine at the University of Pennsylvania's School of Medicine for the past two decade.

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee.

Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic heart disease.

“MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.

“By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments, we may ultimately transform the future of treating cardiovascular disease.”

1st February 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics